Involved in cellular response to insulin stimulus and cellular response to magnesium ion. Predicted to be active in external side of plasma membrane and extracellular space. Biomarker of chronic kidney disease; epilepsy; liver disease (multiple); obesity; and rheumatoid arthritis. Human ortholog(s) of this gene implicated in prostate carcinoma. Orthologous to human AZGP1 (alpha-2-glycoprotein 1, zinc-binding); INTERACTS WITH (+)-schisandrin B; 2,3,7,8-tetrachlorodibenzodioxine; acetamide.
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of AZGP1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of AZGP1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of AZGP1 mRNA
[Diethylnitrosamine co-treated with Phenobarbital] results in decreased expression of AZGP1 mRNA and [Diethylnitrosamine co-treated with Phenobarbital] results in increased methylation of AZGP1 promoter
Peroxiredoxin-2 and zinc-alpha-2-glycoprotein as potentially combined novel salivary biomarkers for early detection of oral squamous cell carcinoma using proteomic approaches.
Downregulation of AZGP1 by Ikaros and histone deacetylase promotes tumor progression through the PTEN/Akt and CD44s pathways in hepatocellular carcinoma.
Circulating and Adipose Tissue mRNA Levels of Zinc-α2-Glycoprotein, Leptin, High-Molecular-Weight Adiponectin, and Tumor Necrosis Factor-Alpha in Colorectal Cancer Patients With or Without Obesity.